Magnitude of the association increased with the number of antiepileptic drugs prescribed
WEDNESDAY, Jan. 4, 2023 (HealthDay News) — Antiepileptic drugs are associated with incident Parkinson disease, according to a study published online Dec. 27 in JAMA Neurology.
Daniel Belete, M.B.Ch.B., from Queen Mary University of London, and colleagues investigated the association between antiepileptic drugs and incident Parkinson disease using data from 1,433 individuals with a Parkinson disease diagnosis and 8,598 matched controls. Routinely collected prescription data derived from primary care were used to define exposure to antiepileptic drugs (carbamazepine, lamotrigine, levetiracetam, and sodium valproate).
The researchers observed an association between antiepileptic drug prescriptions and incident Parkinson disease (odds ratio, 1.80) in a dose-response fashion, with a trend for a greater number of prescription issues and multiple antiepileptic drugs being associated with a greater risk for Parkinson disease.
“To the best of our knowledge, this is the first observational study to investigate a range of antiepileptic drugs and their association with incident Parkinson disease. As such, it sets the scene and highlights the need for further work to corroborate our findings in other large data sets because these findings could have important implications for clinical decision-making,” the authors write. “The underlying reasons for an association between antiepileptic drugs and Parkinson disease should be further explored.”
Two authors disclosed financial ties to the pharmaceutical industry.
Probable Postictal Psychosis Linked to Risk for Subsequent Primary Psychotic Disorders
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Emergency Diagnosis Linked to Worse Outcomes for Range of Conditions
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout